Mod­er­na’s Cin­derel­la sto­ry is get­ting a scary rewrite on Wall Street, and a top an­a­lyst points to one path to a hap­py end­ing

Dur­ing the pan­dem­ic, Mod­er­na wrote it­self a Hol­ly­wood tale of overnight rich­es and fame. The biotech changed the world, saved lives and pre­vent­ed suf­fer­ing on a glob­al scale. And they were re­ward­ed with a top-10 Big Phar­ma val­u­a­tion, with an­a­lysts fore­cast­ing an end­less feast ahead.

But that was so yes­ter­day, ac­cord­ing to the an­a­lysts count­ing ex­pect­ed box of­fice rev­enue in the months and years to come.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE